



US007928066B1

(12) **United States Patent**  
**Clemetson**

(10) **Patent No.:** **US 7,928,066 B1**  
(45) **Date of Patent:** **Apr. 19, 2011**

(54) **RECOMBINANT PLATELET COLLAGEN RECEPTOR GLYCOPROTEIN VI AND ITS PHARMACEUTICAL USE**

(75) Inventor: **Kenneth J. Clemetson**, Bern (CH)

(73) Assignee: **Aventis Pharma Deutschland GmbH**, Frankfurt am Main (DE)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 582 days.

(21) Appl. No.: **09/959,802**

(22) PCT Filed: **Apr. 25, 2000**

(86) PCT No.: **PCT/EP00/03683**

§ 371 (c)(1),  
(2), (4) Date: **Nov. 7, 2001**

(87) PCT Pub. No.: **WO00/68377**

PCT Pub. Date: **Nov. 16, 2000**

(30) **Foreign Application Priority Data**

May 7, 1999 (EP) ..... 99109094

(51) **Int. Cl.**  
**A61K 38/17** (2006.01)  
**C07K 14/705** (2006.01)

(52) **U.S. Cl.** ..... **514/13.8**; 530/350

(58) **Field of Classification Search** ..... None  
See application file for complete search history.

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO 9511259 4/1995

OTHER PUBLICATIONS

Ishibashi et al. International Journal of Hematology 62: 107-115, 1995.\*

Gibbons Jonathan M et al.: "Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain." FEBS Letters, vol. 413 No. 2, 1997, pp. 255-259.  
Jandrot-Perrus Martine et al.: "Adhesion and activation of human platelets induced by convulxin involve glycoprotein VI and integrin alpha-2-beta-1." Journal of Biological Chemistry, vol. 272, No. 43, 1997, pp. 27035-27041.

Gibbons Jonathan M et al.: "The p85 subunit of phosphatidylinositol 3-kinase associated with the Fc receptor gamma-chain and linker for activator of T cells (LAT) in platelets stimulated by collagen and convulxin." Journal of Biological Chemistry, vol. 273, No. 51, Dec. 18, 1998, pp. 24437-24443.

Clemetson Jeannine et al.: "The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors." Journal of Biological Chemistry, vol. 274, No. 41, Oct. 8, 1999, pp. 29019-29024.

Miura Y: "Platelet Glycoprotein VI" EMBL Database, Accession No. AB035073, Jan. 14, 2000.

\* cited by examiner

Primary Examiner — Christine J Saoud

(74) Attorney, Agent, or Firm — Millen, White, Zelano & Branigan, P.C.

(57) **ABSTRACT**

The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit binding of thrombocytes and platelets, respectively, to collagen. Changes in GPIV can be used to monitor platelet age and exposure to thrombotic and cardiovascular diseases.

**17 Claims, 2 Drawing Sheets**



FIGURE 2

GAGCTCAGGA CAGGGCTGAG GAACCATGTC TCCATCCCCG ACCGCCCTCT (50)  
TCTGTCTTGG GCTGTGTCTG GGGCGTGTGC CAGCGCAGAG TGGACCGCTC (100)  
CCCAAGCCCT CCCTCCAGGC TCTGCCCAGC TCCCTGGTGC CCCTGGAGAA  
GCCAGTGACC CTCCGGTGCC AGGGACCTCC GGGCGTGGAC CTGTACCGCC (200)  
TGGAGAAGCT GAGTTCCAGC AGGTACCAGG ATCAGGCAGT CCTCTTCATC  
CCGGCCATGA AGAGAAGTCT GGCTGGACGC TACCGCTGCT CCTACCAGAA (300)  
CGGAAGCCTC TGGTCCCTGC CCAGCGACCA GCTGGAGCTC GTTGCCACGG  
GAGTTTTTGC CAAACCCCTG CTCTCAGCCC AGCCCGGCCC GGGGGTGTCTG (400)  
TCAGGAGGGG ACGTAACCCT ACAGTGTCTG ACTCGGTATG GCTTTGACCA  
ATTTGCTCTG TACAAGGAAG GGGACCCTGC GCCCTACAAG AATCCCGAGA (500)  
GATGGTACCG GGCTAGTTC CCCATCATCA CGGTGACCGC CGCCACAGC  
GGAACCTACC GATGCTACAG CTTCTCCAGC AGGGACCCAT ACCTGTGGTC (600)  
GGCCCCCAGC GACCCCTGG AGCTTGTGGT CACAGGAACC TCTGTGACCC  
CCAGCCGGTT ACCAACAGAA CCACCTTCTT CCGTAGCAGA ATTCTCAGAA (700)  
GCCACCGCTG AACTGACCGT CTCATTACA AACAAAGTCT TCACAACTGA  
GACTTCTAGG AGTATACCA CCAGTCCAAA GGAGTCAGAC TCTCCAGCTG (800)  
GTCCTGCCCG CCAGTACTAC ACCAAGGGCA ACCTGGTCCG GATATGCCTC  
GGGGCTGTGA TCCTAATAAT CCTGGCGGGG TTTCTGGCAG AGGACTGGCA (900)  
CAGCCGGAGG AAGCGCCTGC GGCACAGGGG CAGGGCTGTG CAGAGGCCGC  
TTCCGCCCT GCGGCCCTC CCGCAGACC GGAAATCACA CGGGGGTCAG (1000)  
GATGGAGGCC GACAGGATGT TCACAGCCGC GGGTTATGTT CATGACCGCT  
GAACCCAGG CACGGTCGTA TCCAAGGGAG GGATCATGCC ATGGGAGGCG (1100)  
ACTCAAAGAC TGGCGTGTGT GGAGCGTGGG AGCAGGAGGG CAGAGGCTAC  
AGCTGTGGAA ACGAGGCCAT GCTGCCTCCT CCTGGTGTTC CATCAGGGAG (1200)  
CCGTTCGGCC AGTGTCTGTC TGTCTCTCTG CCTCTCTGTC TGAGGGCAC (1249)

(SEQ ID NO 1)

## RECOMBINANT PLATELET COLLAGEN RECEPTOR GLYCOPROTEIN VI AND ITS PHARMACEUTICAL USE

The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit interaction of platelets and collagen. GPVI on the platelet surface is modified during the platelet lifetime in vivo and can therefore be used as a marker of the platelet age profile.

Glycoprotein VI is a 62/65 kDa (non-reduced/reduced respectively) platelet membrane glycoprotein which forms a complex together with the Fc $\gamma$  common subunit. The GPVI subunit contains the collagen binding site and the Fc $\gamma$  subunit is responsible for signalling. The complex forms one of the major collagen receptors on the platelet surface, critical for platelet activation in response to collagen. The recognition sequence on collagen consists of (GlyProHyp)<sub>n</sub> sequences. Patients are known from Japan who have a genetic deficiency of GPVI. They have mild bleeding problems and their platelets respond only weakly to collagen, presumably via other receptors. A great deal has been learned about the signalling cascades originating at GPVI which strongly resemble those from immune receptors including T-cell receptors, B-cell receptors and natural killer cell receptors. These cascades involve src family tyrosine kinases such as Fyn and Lyn as well as p72<sup>S<sup>17</sup>K</sup> and many other tyrosine kinases and phosphatases and adaptor proteins such as LAT. A main target of these cascades is activation of phospholipase C $\gamma$ 2 which splits phospholipids to give the second messengers diacylglycerol and IP<sub>3</sub>. GPVI is thought to be involved in activation of the platelet integrin  $\alpha$ 2 $\beta$ 1 which has a major role in platelet adhesion to damaged vessel wall. Mice with the Fc $\gamma$  subunit "knocked-out" have platelets which still show responses to collagen implying that the resting state of  $\alpha$ 2 $\beta$ 1 may also be regulated by the GPVI/Fc $\gamma$  complex.

The platelet collagen receptor GPVI is closely related to the natural killer activating receptors of the p58KAR family as well as to Fc $\alpha$ R.

The adhesion and activation of resting, circulating platelets at a site of vascular injury is the first step in a process leading to the formation of a thrombus which is converted into a haemostatic plug. Collagen is one of the major components of the vessel wall responsible for platelet activation. Many types of collagen exist and seven of these are found in the subendothelial layers. Several different receptors for collagen have been identified on platelets but the major ones are to now considered to be the integrin  $\alpha$ <sub>2</sub> $\beta$ <sub>1</sub> and the non-integrin GPVI. Although  $\alpha$ <sub>2</sub> $\beta$ <sub>1</sub> is well characterised and both subunits were cloned and sequenced several years ago, the structure of GPVI has remained elusive although several features have been identified. It was determined about twenty years ago that GPVI is a major platelet glycoprotein with a molecular mass in the 60-65 kDa range and an acid pI. Its role as a putative collagen receptor was established following the identification of a patient in Japan with a mild bleeding disorder whose platelets showed a specific defect of response to collagen and lacked this receptor. This patient had also developed autoantibodies to the deficient receptor and these were used to characterise the molecule further. More recently it was established that GPVI is associated non-covalently with the common Fc $\gamma$

subunit which acts as the signalling part of the complex. It was also demonstrated that the recognition sequence on collagen for GPVI is a repeated Gly-Pro-Hyp triplet within the collagen triple helical structure and that synthetic peptides based on this structure could be used as specific GPVI directed agonists. The GPVI/Fc $\gamma$  complex was shown to signal to the platelet interior by an immune receptor-like mechanism, involving activation of p72<sup>S<sup>17</sup>K</sup> and leading by a cascade of kinase/phosphatase/adaptor protein interactions to activation of PLC $\gamma$ 2 and hence to release of granules and platelet aggregation. A further step in characterisation of this molecule was the demonstration that the snake C-type lectin, convulxin, from the Tropical Rattlesnake, *Crotalus durissus terrificus* was able to activate platelets by clustering GPVI through a multimeric interaction. Convulxin was shown to bind specifically to GPVI providing a method for purification of this receptor in conjunction with established approaches.

Thus, it is clear from the prior art that GPVI seems to be a very interesting compound in many therapeutical fields above all concerning with applications which are related, directly or indirectly, to blood coagulation events which depend on collagen—platelet interaction. It was, therefore, the goal of the present invention is to provide GPVI in a recombinant form and to show its efficiency as direct therapeutical target or as tool for screening of short compounds, especially chemically synthesized or synthesizable compounds having the capability to inhibit or block the natural platelet-collagen interaction.

The invention relates also to portions or fragments of the GPVI protein which to have maintained their biological activity which is the binding to collagen.

The invention was successful in purifying adequate amounts of GPVI for preliminary characterisation and for peptide sequencing. The sequences were used to design primers for PCR to identify a positive sequence in a DNA library. This DNA sequence was then used as a probe to isolate an almost complete cDNA sequence from the library and missing 5'-sequence was obtained using a RACE method from a platelet cDNA library.

The invention also shows the use of recombinant GPVI as therapeutically applicable compound which is capable, when administered in a patient with e.g. damaged blood vessels, to bind to collagen, thus preventing platelets bearing membrane-bound GPVI from binding to said collagen.

The recombinant soluble extracellular domain of GPVI contains the collagen binding site and can prevent platelet activation by collagen. It could therefore be applicable to treatment of disease conditions involving increased platelet activation with collagen, such as atherosclerotic plaque rupture, in diseases such as unstable angina or, during surgical treatment such as Percutaneous Transluminal Coronary Angioplasty (PTCA), where arteries are reopened by inflation of a balloon catheter causing considerable damage to the vessel wall and much platelet activation and often resulting in reclosure of the vessel later. The advantage of recombinant GPVI fragments compared to present treatment methods is that they act at an earlier stage by preventing or reducing platelet activation rather than by suppressing events after platelet activation, such as aggregation by GPIIb-IIIa antagonists. Thus, smaller amounts of platelet granule contents are released including growth factors and chemokines which are involved not only in wound repair but in the remodelling of the vessel wall by smooth muscle migration and in attraction of phagocytic cells such as monocytes known to contribute to atherosclerosis. Fab fragment of humanised mouse monoclonal antibodies against GPVI could be used with similar effect to block GPVI on the platelet surface with similar applications as above.

Recombinant GPVI according to this invention can also be used in a binding assay to collagen to screen for small molecules (in combinatorial libraries for example) capable of inhibiting this interaction and which can be used to develop therapeutic compounds which are inhibitors of the collagen-platelet interaction. By suitable derivatisation these compounds are made orally available. Again the main objective is to prepare compounds reducing GPVI-collagen interactions and hence platelet activation in situations where platelets come into contact with collagen. The screening technology as such used in this invention is well established in the prior art. By such screening assays the invention enables finding and developing new targets which can inhibit the natural membrane-bound GPVI on the platelet surface as a collagen antagonist. Such targets which may be small chemical molecules may then be the basis for further inventions.

Another major application of GPVI and reagents that recognize specific domains of GPVI is as markers of platelet age and functionality. Young platelets are generally thought to be more active and functional than older ones. Young platelets bind to and are activated by the snake venom C-type lectin convulxin, which is specific for GPVI, and as they age both the binding and degree of activation decrease. This can be due to either proteolytic or conformational changes in GPVI or its association with Fc $\gamma$  due to platelet activation or damage in the circulation. This can be a useful parameter to measure the age and function profile of platelets in patients as well as in normal persons during medical controls. The platelet age profile changes in many diseases affecting the bone marrow or the immune system and could be an important diagnostic criterion if better methods for its determination were available. For example, patients with diseases involving increased platelet turnover will show more young platelets whereas patients on chemotherapy or radiation treatment will show a steadily aging population. Thus, such an age profile can be used for a precise monitoring of treatment. In a normal healthy population very little is known about the age profile distribution and its role as a predictor of changes in health. It is not known whether the changes in GPVI are due to the partial involvement of platelets in haemostatic events and whether changes might be more pronounced in patients with extensive cardiovascular disease. At present thiazole orange is used to detect young reticulated platelets containing mRNA. This mRNA soon decays, restricting the method to only the youngest platelets. Reagents which could be used in such an assay would include GPVI-specific snake venom proteins such as convulxin, or monoclonal or polyclonal antibodies recognising the N-terminal region of GPVI or monoclonal antibodies recognising new sites or conformations exposed by proteolysis of the N-terminal domain or specific conformations present either in the intact molecule and not in the aged one or vice versa or small chemical entities selected to recognise specifically intact GPVI or its modified form. These reagents would be labelled with a fluorescent marker, or together with a fluorescent labelled second antibody or affinity reagent and used in flow cytometry to measure the platelet binding profile. At a later stage alternative, less labour intensive measuring techniques based on automated measuring of platelet profiles could be adopted. Using cell sorting methods with flow cytometry or magnetic beads it should be possible to isolate young and old platelets to examine the factors involved in removal of old platelets from the circulation. Reagents recognizing specific forms of GPVI would be a key to such studies.

Therefore, it is an object of the present invention to provide a DNA coding for Glycoprotein VI or biological active fragments thereof, especially the sequence of FIG. 2.

It is a further object of this invention to provide a DNA coding for Glycoprotein VI comprising the amino acid sequences of FIGS. 1A and 1B.

It is another object of this invention to provide a pharmaceutical composition comprising recombinant GPVI together with a pharmaceutically acceptable diluent, carrier or excipient, and its use for the manufacture of a medicament in the therapeutic field of thrombotic and cardiovascular events and disorders related to platelet-collagen interactions

Another object of the invention is the use of recombinant GPVI in a screening tool for detecting specific inhibitors of platelet-collagen interactions.

Another object of the invention is the use of GPVI as a marker for platelet age and exposure to cardiovascular diseases.

Possible medical indications and applications, respectively, are, for example, unstable angina pectoris, PTCA, use of stents in this field, operations on coronary vessels, general operations on blood vessels, operations which may damage larger blood vessels such as hip joint operations. Moreover, all indications are included which relate to thromboembolic events caused by disorders of the interaction between the vessel wall and the coagulation system with a high risk of formation of thrombi and blocking of vessels.

As indicated above, the GPVI protein and fragments thereof according to the present invention are suitable as pharmaceutically effective compounds in pharmaceutical compositions and combinations.

The pharmaceutical formulations according to the invention optionally may comprise additional active ingredients like anti-coagulants such as hirudin or heparin or thrombolytic agents such as plasminogen activator or hementin or antagonists to other platelet receptors such as GPIIb-IIIa antagonists like abciximab or eptifibatid or ADP-receptor antagonists such as clopidogrel.

The novel protein, and its biological active fragments respectively, according to the invention may form pharmaceutically acceptable salts with any non-toxic, organic or inorganic acid. Inorganic acids are, for example, hydrochloric, hydrobromic, sulphuric or phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Examples for organic acids are the mono, di and tri carboxylic acids such as acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic and sulfonic acids such as methane sulfonic acid. Salts of the carboxy terminal amino acid moiety include the non-toxic carboxylic acid salts formed with any suitable inorganic or organic bases. These salts include, for example, alkali metals such as sodium and potassium, alkaline earth metals such as calcium and magnesium, light metals of Group IIIA including aluminium, and organic primary, secondary and tertiary amines such as trialkylamines, including triethylamine, procaine, dibenzylamine, 1-ethenamine, N,N'-dibenzylethylene-diamine, dihydroabietylamine and N-alkylpiperidine.

As used herein, the term "pharmaceutically acceptable carrier" means an inert, non toxic solid or liquid filler, diluent or encapsulating material, not reacting adversely with the active compound or with the patient. Suitable, preferably liquid carriers are well known in the art such as sterile water, saline, aqueous dextrose, sugar solutions, ethanol, glycols and oils, including those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil and mineral oil.

The formulations according to the invention may be administered as unit doses containing conventional non-toxic

pharmaceutically acceptable carriers, diluents, adjuvants and vehicles which are typical for parenteral administration.

The term "parenteral" includes, herein subcutaneous, intravenous, intra-articular and intratracheal injection and infusion techniques. Also other administrations such as oral administration and topical application are suitable. Parenteral compositions and combinations are most preferably administered intravenously either in a bolus form or as a constant fusion according to known procedures. Tablets and capsules for oral administration contain conventional excipients such as binding agents, fillers, diluents, tableting agents, lubricants, disintegrants, and wetting agents. The tablets may be coated according to methods well known in the art.

Oral liquid preparations may be in the form of aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or another suitable vehicle before use. Such liquid preparations may contain conventional additives like suspending agents, emulsifying agents, non-aqueous vehicles and preservatives.

Topical applications may be in the form of aqueous or oily suspensions, solutions, emulsions, jellies or preferably emulsion ointments.

Unit doses according to the invention may contain daily required amounts of the protein according to the invention, or sub-multiples thereof to make up the desired dose. The optimum therapeutically acceptable dosage and dose rate for a given patient (mammals, including humans) depends on a variety of factors, such as the activity of the specific active material employed, the age, body weight, general health, sex, diet, time and route of administration, rate of clearance, the object of the treatment, i.e., therapy or prophylaxis and the nature of the thrombotic disease to be treated, antiplatelet or anticoagulant activity.

Therefore, in compositions and combinations useful as anticoagulants in a treated patient (in vivo) a pharmaceutical effective daily dose of the peptides of this invention is between about 0.01 and 100 mg/kg body weight, preferably between 0.1 and 10 mg/kg body weight. According to the application form one single dose may contain between 0.5 and 10 mg of the collagen inhibitor. To achieve an anticoagulant effect in extracorporeal blood a pharmaceutically effective amount of the inventive peptides is between 0.2 and 150 mg/l, preferably between 1 mg and 20 mg/l extracorporeal blood.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: Protein sequence of GPVI (one-letter-code)

1A: Leader sequence

1B: Mature protein

Open reading frame: 339 amino acids

Asterisk: Glycosylation site

Double underline: Transmembrane domain

Underline: Aequenced peptides

FIG. 2: GPVI nucleotide sequence covering open reading frame of 1017 bp plus 3' and 5' regions total 1249 bp (SEQ ID NO:1).

#### DETAILED DESCRIPTION OF THE INVENTION

Two sequences of 7 amino acids showing the least degeneracy in the genetic code were chosen for the synthesis of DNA primers in order to amplify part of the of GPVI cDNA by PCR. As the location of both peptides in the protein were totally unknown, for each of them, two degenerate primers, one sense and one antisense were prepared. These primers

were used to amplify a human bone-marrow library. The combination of the sense 5' TYA THC CNG CNA TGA ARMG 3' (SEQ ID NO: 4) primer coding for the sequence PAMKRSL (SEQ ID NO: 5) with the antisense 5' TTR TAN ARN GCRAAY TGR TC 3' (SEQ ID NO: 6) one corresponding to DQFALYK (SEQ ID NO: 7) amplified a DNA fragment of 221 bp. In addition to the selected peptides, the amplified DNA coded for the LysC/AspN peptide DQLELVATGV-FAKPSLSAQPGPAVSS (residues 81-106 of SEQ ID NO: 3), clearly linking the sequence to the cDNA for GPVI.

Screening 600.000 pfu from a bone marrow library with this 221 bp DNA fragment produced 4 positive pfu. Three had inserts of 1350 bp whether cut by the restriction enzymes Sal I or EcoR I and belonged to the IgG superfamily. The fourth one had an 4.6 kb insert by Sal I digestion and gave two fragments of 2300 bp and 1300 bp respectively when treated by EcoRI. Its DNA encoded the sequence for the 10 peptides derived from amino acid sequencing of GPVI but stopped short of the amino terminal. No starting methionine or leader sequence could be found but more than 2000 bp of previously sequenced non-reading frame DNA terminating in an Alu sequence were present. The 5' end RACE experiment was completed on platelet poly A RNA with primers located in a part of the GPVI sequence which had been corroborated by that of the peptides. A fragment of 348 bp including 278 bp on the sequence of the fourth clone and 70 bp new from by 1987 corresponding to 14 amino acids including the first methionine were found before falling back on the established GPVI sequence. Thus, a cDNA containing a total of 1249 bp, a 25 bp 5' sequence upstream of the start codon, an open reading frame of 1017 bp coding for a protein, including leader sequence, with 339 amino acids, and a 3' region of 207 bp including the stop codon could be sequenced.

A cDNA coding for platelet GPVI was cloned and sequenced from a human bone marrow cDNA library using RACE with platelet mRNA to supply missing 5' sequence. The open reading frame of 1017 bp encodes 339 amino acids and a to untranslated 3' region. Hydrophobicity analysis of the amino acid sequence revealed the presence of two putative transmembrane domains, a putative 20 amino acid signal sequence, and a 19 amino acid domain between residues 247 and 265 of the mature protein. The sequence and its amino acid translation are shown in FIG. 2 and FIG. 1. A comparison with the amino acid sequence of the most similar molecules found in a search of GenBank reveals clearly that it belongs to the immunoglobulin superfamily and the extracellular domain contains two Ig C2-domain loops formed by two disulphide bridges. It is a membrane crossing protein class one molecule with the N-terminus at the exterior and traverses the membrane once. The most closely related molecules belong to the natural killer receptor class which contains both inhibitory and activatory types.

GPVI clearly belongs to the activatory subclass not only through its function but also because unlike the inhibitory class it does not contain ITIM sequences in its cytoplasmic domain. Neither does it contain any tyrosine residues which might be involved in phosphorylation. There are some threonine and serine residues in this domain but they do not match any criteria for kinase consensus sequences. Like the activatory class of NK receptors, GPVI contains an arginine residue as the third amino acid of the membrane crossing domain which is involved in the complex formation with the Fcγ subunit. The cytoplasmic domain contains 51 amino acids, showing only a minor similarity (in the region just below the membrane) to the cytoplasmic domains of other members of this family. This suggests that this domain in GPVI may associate with different types of cytoplasmic molecule than

the other family members. GPVI contains only a single putative N-glycosylation site at Asn69. The domain just above the membrane after the beta sheets of the Ig domains finish, however, is rich in threonine and serine residues which could provide O-glycosylation sites such as are found in GPIb $\alpha$  and GPV. The main function of this O-glycosylation seems to be to present the receptor structures well-extended from the platelet surface to facilitate the interactions with their bulky ligands. Since GPVI was earlier established as a sialoglycoprotein, the difference in molecular mass between the theoretical amino acid mass (37 kDa) and the mass determined by gel electrophoresis (65 kDa reduced) must be due to this glycosylation.

The structure of natural killer receptors of the two domain type has been established by X-ray crystallographic studies and the two Ig-domains were shown to form an acute angle with the receptor site for the peptide-carrying HLA antigens lying on the outside of the elbow. A direct comparison of the structure of the HLA peptide binding site with that of collagen immediately suggests why is these receptors have a common origin because the multiple alpha-helical structures of the HLA binding site and the peptide it contains strongly resemble the triple helical structure of collagen. The natural killer receptors are postulated to work by a dimerisation mechanism with two receptors recognising two separate HLA sites on the cell which the natural killer cell is investigating. Possibly this dimerisation is part of the activation or deactivation mechanism, depending on the class of receptor. In the case of GPVI there may as well be the possibility for two GPVI molecules to associate with one Fc $\gamma$ , since each monomer of the Fc $\gamma$  dimer has a recognition sequence. However, the stoichiometry is not yet known, and based upon the structure of collagens, collagen-like peptides that act via GPVI and convulxin, it seems likely that the strength of the signal is related to the number of GPVI/Fc $\gamma$  complexes that are clustered together. Other platelet receptors belonging to this Ig family include ICAM-2 (CD102) and PECAM (CD31).

All microorganisms, cell lines, expression systems, expression hosts, plasmids, promoters, resistance markers, replication origins, restriction sites or other fragments or parts of vectors which are mentioned in the description not directly in connection with the claimed invention are commercially or otherwise generally available. Provided that no other hints are given, they are used only as examples and are not essential with respect to the invention, and can be replaced by other suitable tools and biological materials, respectively.

The techniques which are essential according to the invention are described in detail below and above. Other techniques which are not described in detail correspond to known standard methods which are well known to a person skilled in the art, or are described more in detail in the cited references and patent applications and in the standard literature (e.g. Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, 2nd Edition, Cold Spring Harbor; Harlow, Lane, 1988, *Antibodies: A Laboratory Manual*, Cold Spring Harbor).

## EXAMPLES

### Example 1

#### Materials

Protein A-Sepharose, peroxidase-conjugated goat anti-mouse and anti-rabbit antibodies, bovine serum albumin, *Crotalus durissus terrificus* venom, wheat germ agglutinin (WGA), N-hydroxysuccinimidyl chloroformate-activated

cross-linked 4% beaded agarose and Triton X-114 were from Sigma Chemical Co. (St Louis, Mo.), Octanoyl-N-methylglucamide (ONMG) and nonanoyl-N-methylglucamide (NNMG) were from Oxyl Chemie (Bobingen, Germany).

### Example 2

#### GPVI Isolation from Platelets

Membrane glycoproteins were isolated from platelets as previously described. Briefly, platelets (from 40 buffy coats) were washed and lysed in 2% Triton X-114 in the presence of protease inhibitors. The Triton X-114 and aqueous phases were separated and the detergent phase was loaded on a column of wheat-germ agglutinin coupled to Sepharose 4B. The platelet glycoproteins were eluted with 10 mM Tris HCl, pH 7.4, 30 mM NaCl, 0.2% octanoyl-N-methylglucamide (ONMG) and 2% N-acetylglucosamine. After dialysis and concentration, the solution of glycoproteins was loaded on a column of convulxin bound to N-hydroxylsuccinimidyl-p-nitrophenyl chloroformate activated cross-linked 4% beaded agarose (1 mg/ml). The column was washed with 4 volumes of 10 mM Tris HCl, pH 7.4, 30 mM NaCl, 0.2% nonanoyl-N-methylglucamide (NNMG), and then with 4 volumes of 10 mM Tris HCl, pH 7.4, 30 mM NaCl and 2% NNMG. GPVI was eluted with 0.08% SDS in 10 mM Tris/HCl, pH 7.4. The solution was concentrated and loaded on a preparative gel of 8.5% polyacrylamide using the Model 491 Prep Cell (Bio-Rad, CA). The preparative electrophoresis was performed under non-reduced conditions following the manufacturer instructions. GPVI eluted as a single band at 65 kDa. The fractions were pooled, concentrated on Centricon-30 (Amicon, Beverly, Mass.) and resuspended in 10 mM Tris/HCl, pH 7.4 and 0.1% ONMG.

### Example 3

#### Amino Acid Analysis of GPVI

GPVI was digested with the endoproteinases LysC and AspN (Boehringer Mannheim, Germany). The 10 peptides generated were separated by reverse-phase HPLC and sequenced on an Applied Biosystem model 477A pulsed-liquid-phase protein sequencer with a model 120A on-line phenylthiohydantoin amino acid analyser.

### Example 4

#### Amplification of a 221 bp Fragment Coding for part of GPVI from a $\lambda$ gt11 cDNA Library

A sample ( $10^{10}$  pfu) (plaque forming units) from a human bone marrow library (Clontech, Palo Alto, Calif.) was amplified using 2 combinations of 4 degenerate primers. The final primer concentrations were 2  $\mu$ M, the dNTP concentration was 200  $\mu$ M and 2 U/100  $\mu$ l reaction AmpliTaq Gold (Perkin Elmer, Rotkreuz, Switzerland) were used. The PCR conditions were 5 cycles at 37 $^{\circ}$  C. followed by 30 cycles at 44 $^{\circ}$  C. The sense 19mer 5' TYATHCCNGCNATGAARMG 3' (SEQ ID NO: 4) and the antisense 20mer 5' TTR-TANARNGCRAAYTGRTC 3' (SEQ ID NO: 6) amplified a 221 bp fragment which was subcloned in Bluescript KS<sup>+</sup> (Stratagene, La Jolla, Calif.) and sequenced using the T7 Sequenase kit (Amersham, Switzerland).

## Example 5

Screening the  $\lambda$ gt11 cDNA Library with the 221 bp GPVI Probe

The 221 bp fragment was cut from the plasmid, cleaned and labelled with  $\alpha^{32}$ P-ATP (20 MBq/50  $\mu$ l, Hartmann Analytik, Braunschweig, Germany) using the High Prime Labeling kit (Boehringer Mannheim, Switzerland). The human bone marrow library was screened following the manufacturer instructions. Positive phages were grown, their DNA isolated and subcloned in BlueScript using either EcoRI or Sal I sites and sequenced. Sequencing was performed using the ABS system of RACE-Platelet poly A RNA was prepared as previously described (Power et al., Cytokine 7, 479-482, 1995). Reverse transcription (30  $\mu$ l) was performed using 5  $\mu$ g of poly A RNA with the primer 5'TGAATGAGACGGT-CAGTTCAGC 3' (SEQ ID NO: 8) (20  $\mu$ M), dNTP (1 mM), RNAsin (40 U), 1 $\times$ AMV buffer and 20 U AMV reverse transcriptase for 20 min at 45° C. followed by 20 min at 52° C. The reaction mixture was treated with 2  $\mu$ l 6N NaOH at 65° C. for 30 min, neutralised with 2  $\mu$ l 6N acetic acid, and concentrated in a Centricon 30 (Amicon). An anchor was ligated to the first strand DNA following the protocol of Aptes and Siebert (BioTechniques 15: 890-893, 1993). Nested PCR was performed using a primer complementary to the anchor and the primer 5' TTGTACAGAGCAAATTGGTC 3' (SEQ ID NO: 9) (35 cycles, 55° C.) and followed by the primer 5' GACCAGAGGCTTCCGTTCTG 3' (SEQ ID NO: 10) (30 cycles at 53° C.). The highest band (350 bp) was separated by agarose electrophoresis from the lower ones, subcloned into BlueScript, and sequenced.

## Example 6

Preparation of Anti-GPVI Fab and F(ab)<sub>2</sub>

Polyclonal antisera against human GPVI were generated in rabbits. IgG from rabbit anti-GPVI antiserum was purified as described. Digestion of IgG with immobilized papain (Pierce) to generate Fab fragments was performed according to the standard protocol of the supplier. Fab fragments were separated from undigested IgG and Fc fragments using an immobilized Protein A (Sigma) column. The flowthrough was transferred to a dialysis tube, concentrated using solid

polyethyleneglycol 20,000, thoroughly dialysed against 20 mM Hepes, 140 mM NaCl, 4 mM KCl, pH 7.4 and stored at 4° C. until used. F(ab')<sub>2</sub> fragments were prepared by pepsin digestion of IgG, 1:50 enzyme to substrate ratio (w/w), in 0.5 M acetate buffer, pH 4.0, at 37° C. for 18 hr. The pH was corrected to 7.4 with diluted NaOH and the sample was dialysed against 20 mM phosphate, pH 7.4. F(ab')<sub>2</sub> fragments were separated from undigested IgG and Fc fragments using Protein A chromatography. The flow-through was transferred to dialysis tube, concentrated using solid polyethyleneglycol 20 000, intensively dialysed against 20 mM Hepes, 140 mM NaCl, 4 mM KCl, pH 7.4 and stored in aliquots at -20° C. Washed platelets were lysed in Triton X-114 and phase separation was performed on the soluble material before isolating the membrane glycoproteins associated with the Triton X-114 phase by affinity chromatography on wheat germ agglutinin-Sepharose 4B as described previously. As GPVI represents a very small fraction of the platelet membrane glycoprotein pool, we used the specificity of the snake C-type lectin convulxin for isolation of this receptor. Affinity chromatography on convulxin coupled to Sepharose 4B yielded a 65 kDa protein as major product. However, uncharacterized material of both higher and lower Mr co-eluted with GPVI and could not be removed by extensive washing of the column. Preparative gel electrophoresis on 8.5% polyacrylamide was added as a final step of purification; Fractions containing GPVI were pooled and gave a single band on reanalysis. Purified GPVI was tested for its ability to block platelet aggregation by collagen. A slight inhibitory effect was observed when aliquots of GPVI solution were added to the platelet suspension: However, by preincubating GPVI with collagen before adding the mixture to the platelet suspension, aggregation could be inhibited in a dose-dependant manner. These platelets still aggregated when fresh collagen was added. Under non-reducing conditions, the isolated protein has a Mr of 62 kDa with a shift toward a slightly higher Mr (65 kDa) under reducing conditions. As the amino terminus of GPVI was found to be blocked, the protein was digested with the enzymes LysC and LysC/AspN which produced 4 and 6 peptides, respectively, from which sequence was obtained. The peptides were separated by reverse phase HPLC on a C4 column and sequenced using the Edman method. The amino acid sequences of these peptides are underlined in the translated cDNA sequence (FIG. 1).

## SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 10

<210> SEQ ID NO 1

<211> LENGTH: 1249

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (26)..(85)

<223> OTHER INFORMATION: Leader sequence

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (86)..(1042)

<223> OTHER INFORMATION: mature GPVI protein

<400> SEQUENCE: 1

gagctcagga cagggctgag gaacc atg tct cca tcc ccg acc gcc ctc ttc 52  
Met Ser Pro Ser Pro Thr Ala Leu Phe

-continued

tgt ctt ggg ctg tgt ctg ggg cgt gtg cca gcg cag agt gga ccg ctc	100
Cys Leu Gly Leu Cys Leu Gly Arg Val Pro Ala Gln Ser Gly Pro Leu	
10 15 20 25	
ccc aag ccc tcc ctc cag gct ctg ccc agc tcc ctg gtg ccc ctg gag	148
Pro Lys Pro Ser Leu Gln Ala Leu Pro Ser Ser Leu Val Pro Leu Glu	
30 35 40	
aag cca gtg acc ctc cgg tgc cag gga cct ccg ggc gtg gac ctg tac	196
Lys Pro Val Thr Leu Arg Cys Gln Gly Pro Pro Gly Val Asp Leu Tyr	
45 50 55	
cgc ctg gag aag ctg agt tcc agc agg tac cag gat cag gca gtc ctc	244
Arg Leu Glu Lys Leu Ser Ser Ser Arg Tyr Gln Asp Gln Ala Val Leu	
60 65 70	
ttc atc ccg gcc atg aag aga agt ctg gct gga cgc tac cgc tgc tcc	292
Phe Ile Pro Ala Met Lys Arg Ser Leu Ala Gly Arg Tyr Arg Cys Ser	
75 80 85	
tac cag aac gga agc ctc tgg tcc ctg ccc agc gac cag ctg gag ctc	340
Tyr Gln Asn Gly Ser Leu Trp Ser Leu Pro Ser Asp Gln Leu Glu Leu	
90 95 100 105	
gtt gcc acg gga gtt ttt gcc aaa ccc tcg ctc tca gcc cag ccc ggc	388
Val Ala Thr Gly Val Phe Ala Lys Pro Ser Leu Ser Ala Gln Pro Gly	
110 115 120	
ccg gcg gtg tcg tca gga ggg gac gta acc cta cag tgt cag act cgg	436
Pro Ala Val Ser Ser Gly Gly Asp Val Thr Leu Gln Cys Gln Thr Arg	
125 130 135	
tat ggc ttt gac caa ttt gct ctg tac aag gaa ggg gac cct gcg ccc	484
Tyr Gly Phe Asp Gln Phe Ala Leu Tyr Lys Glu Gly Asp Pro Ala Pro	
140 145 150	
tac aag aat ccc gag aga tgg tac cgg gct agt ttc ccc atc atc acg	532
Tyr Lys Asn Pro Glu Arg Trp Tyr Arg Ala Ser Phe Pro Ile Ile Thr	
155 160 165	
gtg acc gcc gcc cac agc gga acc tac cga tgc tac agc ttc tcc agc	580
Val Thr Ala Ala His Ser Gly Thr Tyr Arg Cys Tyr Ser Phe Ser Ser	
170 175 180 185	
agg gac cca tac ctg tgg tcg gcc ccc agc gac ccc ctg gag ctt gtg	628
Arg Asp Pro Tyr Leu Trp Ser Ala Pro Ser Asp Pro Leu Glu Leu Val	
190 195 200	
gtc aca gga acc tct gtg acc ccc agc cgg tta cca aca gaa cca cct	676
Val Thr Gly Thr Ser Val Thr Pro Ser Arg Leu Pro Thr Glu Pro Pro	
205 210 215	
tcc tcg gta gca gaa ttc tca gaa gcc acc gct gaa ctg acc gtc tca	724
Ser Ser Val Ala Glu Phe Ser Ser Glu Ala Thr Ala Glu Leu Thr Val Ser	
220 225 230	
ttc aca aac aaa gtc ttc aca act gag act tct agg agt atc acc acc	772
Phe Thr Asn Lys Val Phe Thr Thr Glu Thr Ser Arg Ser Ile Thr Thr	
235 240 245	
agt cca aag gag tca gac tct cca gct ggt cct gcc cgc cag tac tac	820
Ser Pro Lys Glu Ser Asp Ser Pro Ala Gly Pro Ala Arg Gln Tyr Tyr	
250 255 260 265	
acc aag ggc aac ctg gtc cgg ata tgc ctc ggg gct gtg atc cta ata	868
Thr Lys Gly Asn Leu Val Arg Ile Cys Leu Gly Ala Val Ile Leu Ile	
270 275 280	
atc ctg gcg ggg ttt ctg gca gag gac tgg cac agc cgg agg aag cgc	916
Ile Leu Ala Gly Phe Leu Ala Glu Asp Trp His Ser Arg Arg Lys Arg	
285 290 295	
ctg cgg cac agg ggc agg gct gtg cag agg ccg ctt ccg ccc ctg ccg	964
Leu Arg His Arg Gly Arg Ala Val Gln Arg Pro Leu Pro Pro Leu Pro	
300 305 310	
ccc ctc ccg cag acc cgg aaa tca cac ggg ggt cag gat gga ggc cga	1012
Pro Leu Pro Gln Thr Arg Lys Ser His Gly Gly Gln Asp Gly Gly Arg	
315 320 325	

-continued

cag gat gtt cac agc cgc ggg tta tgt tca tgaccgctga accccaggca 1062  
 Gln Asp Val His Ser Arg Gly Leu Cys Ser  
 330 335

cggctcgtatc caagggaggg atcatggcat gggaggcgac tcaaagactg gcgtgtgtgg 1122

agcgtggaag caggagggca gaggctacag ctgtggaaac gaggccatgc tgctctctcc 1182

tggtgttcca tcagggagcc gttcggccag tgtctgtctg tctgtctgcc tctctgtctg 1242

agggcac 1249

<210> SEQ ID NO 2

<211> LENGTH: 20

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

Met Ser Pro Ser Pro Thr Ala Leu Phe Cys Leu Gly Leu Cys Leu Gly  
 1 5 10 15

Arg Val Pro Ala  
 20

<210> SEQ ID NO 3

<211> LENGTH: 319

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 3

Gln Ser Gly Pro Leu Pro Lys Pro Ser Leu Gln Ala Leu Pro Ser Ser  
 1 5 10 15

Leu Val Pro Leu Glu Lys Pro Val Thr Leu Arg Cys Gln Gly Pro Pro  
 20 25 30

Gly Val Asp Leu Tyr Arg Leu Glu Lys Leu Ser Ser Ser Arg Tyr Gln  
 35 40 45

Asp Gln Ala Val Leu Phe Ile Pro Ala Met Lys Arg Ser Leu Ala Gly  
 50 55 60

Arg Tyr Arg Cys Ser Tyr Gln Asn Gly Ser Leu Trp Ser Leu Pro Ser  
 65 70 75 80

Asp Gln Leu Glu Leu Val Ala Thr Gly Val Phe Ala Lys Pro Ser Leu  
 85 90 95

Ser Ala Gln Pro Gly Pro Ala Val Ser Ser Gly Gly Asp Val Thr Leu  
 100 105 110

Gln Cys Gln Thr Arg Tyr Gly Phe Asp Gln Phe Ala Leu Tyr Lys Glu  
 115 120 125

Gly Asp Pro Ala Pro Tyr Lys Asn Pro Glu Arg Trp Tyr Arg Ala Ser  
 130 135 140

Phe Pro Ile Ile Thr Val Thr Ala Ala His Ser Gly Thr Tyr Arg Cys  
 145 150 155 160

Tyr Ser Phe Ser Ser Arg Asp Pro Tyr Leu Trp Ser Ala Pro Ser Asp  
 165 170 175

Pro Leu Glu Leu Val Val Thr Gly Thr Ser Val Thr Pro Ser Arg Leu  
 180 185 190

Pro Thr Glu Pro Pro Ser Ser Val Ala Glu Phe Ser Glu Ala Thr Ala  
 195 200 205

Glu Leu Thr Val Ser Phe Thr Asn Lys Val Phe Thr Thr Glu Thr Ser  
 210 215 220

Arg Ser Ile Thr Thr Ser Pro Lys Glu Ser Asp Ser Pro Ala Gly Pro  
 225 230 235 240

Ala Arg Gln Tyr Tyr Thr Lys Gly Asn Leu Val Arg Ile Cys Leu Gly

-continued

245					250					255					
Ala	Val	Ile	Leu	Ile	Ile	Leu	Ala	Gly	Phe	Leu	Ala	Glu	Asp	Trp	His
			260					265					270		
Ser	Arg	Arg	Lys	Arg	Leu	Arg	His	Arg	Gly	Arg	Ala	Val	Gln	Arg	Pro
			275				280					285			
Leu	Pro	Pro	Leu	Pro	Pro	Leu	Pro	Gln	Thr	Arg	Lys	Ser	His	Gly	Gly
			290			295					300				
Gln	Asp	Gly	Gly	Arg	Gln	Asp	Val	His	Ser	Arg	Gly	Leu	Cys	Ser	
305					310					315					

<210> SEQ ID NO 4  
 <211> LENGTH: 19  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Description of Artificial Sequence: Degenerate primer  
 <220> FEATURE:  
 <221> NAME/KEY: modified\_base  
 <222> LOCATION: (8)  
 <223> OTHER INFORMATION: a, t, c, g, other or unknown  
 <220> FEATURE:  
 <221> NAME/KEY: modified\_base  
 <222> LOCATION: (11)  
 <223> OTHER INFORMATION: a, t, c, g, other or unknown  
 <400> SEQUENCE: 4  
 tyathccngc natgaarmg 19

<210> SEQ ID NO 5  
 <211> LENGTH: 7  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide  
 <400> SEQUENCE: 5  
 Pro Ala Met Lys Arg Ser Leu  
 1 5

<210> SEQ ID NO 6  
 <211> LENGTH: 20  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Description of Artificial Sequence: Degenerate primer  
 <220> FEATURE:  
 <221> NAME/KEY: modified\_base  
 <222> LOCATION: (6)  
 <223> OTHER INFORMATION: a, t, c, g, other or unknown  
 <220> FEATURE:  
 <221> NAME/KEY: modified\_base  
 <222> LOCATION: (9)  
 <223> OTHER INFORMATION: a, t, c, g, other or unknown  
 <400> SEQUENCE: 6  
 ttrtanarng craaytgrtc 20

<210> SEQ ID NO 7  
 <211> LENGTH: 7  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide  
 <400> SEQUENCE: 7

-continued

Asp Gln Phe Ala Leu Tyr Lys  
1 5

<210> SEQ ID NO 8  
<211> LENGTH: 22  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Description of Artificial Sequence: Primer

<400> SEQUENCE: 8

tgaatgagac ggtcagttca gc 22

<210> SEQ ID NO 9  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Description of Artificial Sequence: Primer

<400> SEQUENCE: 9

ttgtacagag caaattggtc 20

<210> SEQ ID NO 10  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Description of Artificial Sequence: Primer

<400> SEQUENCE: 10

gaccagaggc ttccgttctg 20

35

I claim:

1. An isolated recombinant human Glycoprotein VI protein comprising the amino acid sequence of FIG. 1B (SEQ ID NO:3) which is not glycosylated.

2. A pharmaceutical composition comprising the protein of claim 1 and a pharmaceutically acceptable diluent, carrier or excipient therefore.

3. A pharmaceutical composition of claim 2, further comprising an additional pharmacologically active compound.

4. The isolated non-glycosylated recombinant human Glycoprotein VI protein of claim 1 which has a molecular mass of about 37 KDa.

5. A preparation which consists essentially of a polypeptide consisting essentially of the amino acid sequence of positions 1-249 of SEQ ID NO:3.

6. A preparation which consists essentially of a polypeptide consisting of the amino acid sequence of positions 1-249 of SEQ ID NO: 3.

7. An isolated recombinant human Glycoprotein VI protein comprising the amino acid sequence of FIG. 1B (SEQ ID NO:3) and a leader sequence of FIG. 1A (SEQ ID NO:2).

8. An isolated human Glycoprotein VI polypeptide comprising the amino acid sequence set forth in SEQ ID NO:3 and the leader sequence of SEQ ID NO:2 which is produced by expressing a DNA coding for said human Glycoprotein VI in a host cell.

9. A preparation which consists essentially of human Glycoprotein VI polypeptide comprising the amino acid sequence set forth in SEQ ID NO:3 and the leader sequence of SEQ ID NO:2.

10. A preparation which consists essentially of a mature human Glycoprotein VI polypeptide comprising the mature amino acid sequence of FIG. 1B (SEQ ID NO:3).

11. A preparation of claim 10 wherein the mature human Glycoprotein VI polypeptide is recombinant.

12. A preparation of claim 10 wherein the mature human Glycoprotein VI polypeptide which is produced by expressing a DNA coding for said human Glycoprotein VI polypeptide in a host cell.

13. A preparation which consists essentially of a polypeptide comprising the amino acid sequence of SEQ ID NO: 3.

14. A preparation of claim 13 wherein said polypeptide is recombinant.

15. A preparation which consists essentially of a polypeptide comprising the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 1.

16. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 3 and a leader sequence of SEQ ID NO: 2.

17. An isolated polypeptide comprising the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 1.

\* \* \* \* \*

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**


PATENT NO. : 7,928,066 B1  
APPLICATION NO. : 09/959802  
DATED : April 19, 2011  
INVENTOR(S) : Clemetson

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 18, line 46, reads "Glycoprotein VI polypeptide which is produced by express-" should read  
-- Glycoprotein VI polypeptide is produced by express- --

Signed and Sealed this  
Fourteenth Day of February, 2012

A handwritten signature in black ink that reads "David J. Kappos". The signature is written in a cursive, slightly slanted style.

David J. Kappos  
*Director of the United States Patent and Trademark Office*

专利名称(译)	重组血小板胶原受体糖蛋白vi及其药物用途		
公开(公告)号	<a href="#">US7928066</a>	公开(公告)日	2011-04-19
申请号	US09/959802	申请日	2000-04-25
[标]申请(专利权)人(译)	阿文蒂斯药物德国有限公司		
申请(专利权)人(译)	安万特制药DEUTSCHLAND GMBH		
当前申请(专利权)人(译)	安万特制药DEUTSCHLAND GMBH		
[标]发明人	CLEMETSON KENNETH J		
发明人	CLEMETSON, KENNETH J.		
IPC分类号	A61K38/17 C07K14/705 G01N33/50 A61K38/00 A61P7/02 A61P9/10 C07K14/755 C12N15/09 C12N15/12 G01N15/00 G01N33/15 G01N33/53 G01N33/68 G01N33/86		
CPC分类号	C07K14/70503 C07K14/755 C07K16/2803 G01N33/86 A61K38/00 C07K2317/54 G01N2800/222 G01N2015/0084 G01N2333/4728 G01N2333/78 G01N2500/02 C07K2317/55 A61P7/02 A61P9/08 A61P9/10 C07K14/745 C07K16/28 C07K2317/20 C07K2317/76		
优先权	1999109094 1999-05-07 EP		
外部链接	<a href="#">Espacenet</a> <a href="#">USPTO</a>		

摘要(译)

本发明涉及糖蛋白VI ( GPVI )，其分离，纯化和重组生产方法。特别地，本发明涉及GPVI，优选重组GPVI在治疗与血液凝固障碍如血栓形成和心血管疾病直接或间接相关的病症和病理事件中的用途。细胞外重组蛋白也可用于建立筛选试验以发现膜结合GPVI的潜在抑制剂，以分别抑制血小板和血小板与胶原的结合。 GPIV的变化可用于监测血小板年龄和接触血栓形成和心血管疾病。

FIGURE 1A

1 20  
MSPSPTALFC LGLCLGRVPA (SEQ ID NO 2)

FIGURE 1B

1  
QSGPLPKPFL QALPSSLVPL EKFVTLRCQG PPGVDLYRLE KLSRRYQDQ (50)  
AVLFIPAMKR SLAGRYRCSY QN\*GSLWLSPS DQLELVATGV FAKPSLSAQP (100)  
QPAVSSGGDV TLCCQTRYGF DQFALYKEGD PAPYRNPERW YRASFPITIV (150)  
TAAHSGTYRC YSFSSDPYL WSAPSDPLEL VVTGTSVTPS RLPTEPPSSV (200)  
AEFSEATAEL TVSFTNKVFT TETSRISITTS EKESDSPAGP ARQYYTKGNL (250)  
VRICLGAVIL IILAGFLAED WHSRRKRLPH BGRAVQRPLP PLPPLPQTRK (300)  
SHGGQDGRQ DVHSRGLCS (319) (SEQ ID NO 3)